haematological cancer

This page shows the latest haematological cancer news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts haematology pipeline with $7bn Impact Bio deal

and downgraded sales estimates for its haematological cancer drugs.

The Harmony Alliance gathers to battle blood cancer

nd. general assembly based in Berlin, Germany last week, 120 representatives from the Innovative Medicines Initiative’s ( IMI) Harmony Alliance all gathered to discuss achievements and objectives surrounding blood cancer. ... Michel Van Speybroeck,
AbbVie and Roche plan Venclexta combo filings in leukaemia

Meanwhile, AbbVie is also looking at combining Venclexta with its flagship cancer drug, BTK inhibitor Imbruvica (ibrutinib) for haematological cancer, which has already hit the blockbuster mark with sales topping
Intriguing data with Juno's new CAR-T therapy

Suggests a long treatment effect from the biotech's JCAR017 candidate. CAR-T developer Juno Therapeutics has reported data suggesting the benefits of this type of cancer immunotherapy could extend long ... haematological cancer followed by JCAR017 - an
Celgene joins PD-1 race via partnership with BeiGene

The deal for the drug - which is in late-stage trials in cancer and has been tested in around 500 patients to date - gives haematological cancer specialist Celgene a bigger pipeline ... It is a great deal for BeiGene because it gives it a fast-track into
Takeda's gamble on Ariad pays off with Alunbrig approval

After an accelerated review Alunbrig (brigatinib) has been given a green light as a second-line treatment for ALK-positive, non-small cell lung cancer (NSCLC) after first-line therapy with ... Takeda agreed to buy Ariad earlier this year in a $5.2bn deal,

More from news
Approximately 2 fully matching, plus 30 partially matching documents found.

Deal Watch September 2016

Janssen granted Tracon Pharmaceuticals the rights to develop two oncology programmes for prostate cancer and haematological malignancies. ... Adaptimmune Therapeutics entered into a collaboration with MD Anderson Cancer Center to develop specific

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Senior Account Director development role to Business Director, H...: Excellent package

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Client Services Director – Medical Education Agency – North West...: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Global Business Development Director – Health Education: excellent commission

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Add my company

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....